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Abstract
Background: In the absence of routine ovarian cancer screening, promoting help-seeking in response to ovarian
symptoms is a potential route to early diagnosis. The factors influencing women’s anticipated time to presentation
with potential ovarian cancer symptoms were examined.
Methods: Cross-sectional questionnaires were completed by a sample of women at increased familial risk (n = 283)
and population risk (n= 1043) for ovarian cancer. Measures included demographic characteristics, symptom knowledge,
anticipated time to symptom presentation, and health beliefs (perceived susceptibility, worry, perceived threat, confidence
in symptom detection, benefits and barriers to presentation). Structural equation modelling was used to identify
determinants of anticipated time to symptomatic presentation in both groups.
Results: Associations between health beliefs and anticipated symptom presentation differed according to risk
group. In increased risk women, high perceived susceptibility (r = .35***), ovarian cancer worry (r = .98**), perceived
threat (r = −.18**), confidence (r = .16**) and perceiving more benefits than barriers to presentation (r = −.34**), were
statistically significant in determining earlier anticipated presentation. The pattern was the same for population risk
women, except ovarian cancer worry (r = .36) and perceived threat (r = −.03) were not statistically significant determinants.
Conclusions: Associations between underlying health beliefs and anticipated presentation differed according to risk
group. Women at population risk had higher symptom knowledge and anticipated presenting in shorter time frames
than the increased risk sample. The cancer worry component of perceived threat was a unique predictor in
the increased risk group. In increased risk women, the worry component of perceived threat may be more
influential than susceptibility aspects in influencing early presentation behaviour, highlighting the need for
ovarian symptom awareness interventions with tailored content to minimise cancer-related worry in this population.
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Background
Once described as ‘the silent killer’ [1, 2] ovarian cancer
is now recognised as having identifiable symptoms that
are present at all stages of the disease [2]. The import-
ance of symptom awareness in the early diagnosis of
cancer has been highlighted through the UK National
Awareness and Early Diagnosis Initiative and the
American Cancer Society guidelines for early detection
[3, 4]. Ovarian cancer symptoms are vague and poorly
differentiated from other common conditions [5], and
are often misattributed to ageing, the menopause, or
stress [6–8]. Understanding the determinants of antici-
pated ovarian symptomatic presentation (how long it
would take to present to a doctor if they thought they
were experiencing a symptom) is important because
ovarian cancer screening is not yet proven or routinely
available for women in the general population or those
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at increased risk due to a family history of [breast/ovarian]
cancer or gene mutations [9, 10]. Understanding the deter-
minants of anticipated symptomatic presentation is benefi-
cial, with much to be gained from the early detection of
ovarian cancer, such as improved treatment options and
better survival outcomes [11]. While a number of studies
have examined cancer knowledge and symptom presenta-
tion in the general population [12–14], few studies have
been conducted involving women at increased risk for
ovarian cancer. In the general population, low levels of
ovarian cancer symptom knowledge have been reported
[15], as well as a reported lack of association between
awareness of gynaecologic cancer symptoms and antici-
pated presentation behaviour [16]. It could be expected
that the increased saliency of cancer risk would lead to
earlier symptom presentation in women at increased risk;
however, empirical evidence is lacking regarding the influ-
ences on symptom presentation in women at increased
risk compared to the general population.
The Health Belief Model (HBM) [17] can be used to
explore the determinants of anticipated symptomatic
presentation. The HBM proposes that two variables
directly influence likelihood of anticipated presentation
behaviour: (1) perceived threat, and (2) the belief that
the benefits of carrying out the action outweigh the bar-
riers. According to the HBM, worry may be related to
perceived health threat [18–20], which is the combin-
ation of perceived susceptibility and perceived severity
[17, 21]. A review of empirical literature on the role of
cancer worry in screening uptake, and the theoretical
approaches to understanding of worry suggested that
worry is an emotional representation of susceptibility or
severity [22]. Evidence suggests higher perceived threat
increases the likelihood of engaging in behaviour that is
likely to manage or reduce this threat [17]. Cancer-related
worry appears to be a strong influence on health-related
decision making for women at increased risk [23, 24], with
high levels of ovarian cancer worry and perceived suscep-
tibility [25, 26] predicting higher ovarian screening uptake
[23]. Given the impact of risk and associated worry on
cancer screening uptake, the impact of risk and worry on
symptom presentation behaviour needs to be considered
[27]. If high levels of cancer worry are contributing to
presentation in these women, it is important to identify
the mechanisms through which worry can be reduced or
managed. Increased risk women may demonstrate a differ-
ent pattern of health beliefs in relation to ovarian cancer
symptomatic presentation compared to women at popula-
tion risk. Research is therefore needed to explore and
compare these two populations, and to increase under-
standing of the determinants of anticipated presentation,
particularly the potential role of emotions such as cancer-
related worry [28]. In ovarian cancer, there is currently no
agreed definition of an optimal symptom presentation
interval. However, as early stage at diagnosis is associated
with better treatment outcomes and ultimately, survival
[11, 29], early presentation is considered advantageous [4].
Structural equation modelling (SEM) will be used to test
the HBM model and to identify correlates of anticipated
presentation. SEM is a statistical technique that allows for
the simultaneous test of multiple causal relations [30] and
can be used to test theoretical models, such as the HBM
in novel health contexts. SEM is an advantageous method
as it allows for a deeper exploration of the relationships
between variables than standard regression analysis.
Particularly, SEM allows for theoretical models to be
tested, for simultaneous analysis to be conducted, and for
latent (unobserved) variables to be modelled.
The present study was undertaken to examine determi-
nants of anticipated time to presentation for potential
ovarian cancer symptoms in women at increased risk, with
a population risk comparison group. Women at increased
risk were hypothesised to differ from women at popula-
tion risk in terms of health beliefs, including higher levels
of worry, knowledge, perceived susceptibility, perceived
threat, benefits and barriers to presentation, a greater
degree of personal experience of ovarian cancer, and earl-
ier anticipated time to symptom presentation.
Methods
Participants and procedures
Recruitment and study procedures were different for the
increased risk and population risk women and are pre-
sented separately. The study received ethical approval
from Cardiff University, School of Medicine.
Increased risk sample
Participants were recruited from a database of 1999
women who had previously been identified as being at
increased risk of ovarian cancer based on their family
history or genetic test results, and who had taken part in
a psychological evaluation of familial ovarian cancer
screening (PsyFOCS) study [31]. High risk women have
at least a 10-15% lifetime risk of ovarian cancer, com-
pared to 1.3% in women at population risk [32]. Of the
PsyFOCS sample, 446 registered interest in taking part
in a further study on ovarian symptom awareness. In
addition, a further 29 participants were recruited via the
UK based charity Ovacome (http://www.ovacome.or-
g.uk). Women who had registered interest in the study
were invited to complete a postal or online question-
naire, according to their preference. Selection criteria for
the present study included the ability to give informed
consent, not having a previous diagnosis of ovarian can-
cer, or a procedure to remove one or both ovaries. In
total 164 (34.5%) did not return the questionnaire and
28 (5.9%) were excluded due to previous oophorectomy.
The final sample was n = 283 (63.3%). Of these, 29 were
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from Ovacome (10.2%) and the remaining 254 (89.8%)
from the PsyFOCS recruitment pool. Four participants
completed the electronic version of the survey. The
mean age of the women was 52.87 years (SD = 10.40),
with most having completed secondary education or
above (71.0%, n = 201) (see Table 1).
Population risk sample
Women from the general population were recruited in
Wales as part of the International Cancer Benchmarking
Partnership [28]. Random probability sampling was used
to achieve a population-representative sample using elec-
tronic telephone directories as the sampling frame. Where
more than one person was eligible, the Rizzo method was
used to randomly select one person to be interviewed,
thereby giving an equal chance of selection to all eligible
people living in the household [33]. Computer assisted
telephone interviews were completed by 1043 women.
The selection criteria included women aged over 50 years,
residing in Wales with the ability to give informed con-
sent, not having had a previous diagnosis of ovarian can-
cer and not having had a procedure to remove one or
both ovaries [28]. Due to the sampling method used for
the general population (random digit dialling), it is not
possible to estimate the number of eligible participants
[28]. Of the 1385 female respondents, 315 were excluded
due to a personal history of ovarian cancer or having had
a procedure to remove one or both ovaries. The final sam-
ple comprised 1043 women. As shown in Table 1, the
mean age of the women was 64.53 (SD = 9.49) and the
majority had completed education up to age 16 (55.8%, n
= 570). The increased risk sample was significantly youn-
ger, more likely to be married or cohabiting, and to have a
higher educational level.
Health belief model measures
Individual perceptions
Two measures were used to assess individual percep-
tions. Perceived susceptibility was measured by asking
“Compared to most other women your age, how likely
do you think it is that you will get ovarian cancer at
some time in your life?” Responses were rated from 1
(much less likely) to 5 (much more likely) (adapted from
[34]. Ovarian cancer worry was measured with the
Ovarian Cancer Worry Scale [35], which is an adapta-
tion of the Cancer Worry Scale [36]. The Ovarian
Cancer Worry Scale consists of three questions,
which assess frequency of worry, the impact this has
on mood and the impact on daily functioning, each
on a 5 point scale giving a range of 3-15 (Cronbach’s
α = 0.80 for the increased risk sample, α = 0.69 for the
population risk sample).
Modifying factors
Eleven statements assessed ovarian cancer symptom
knowledge, and were adapted from the validated ovar-
ian cancer awareness measure [37] and included less
common symptoms to reflect the UK Department of
Health’s ‘Key Messages’ on ovarian cancer for health
professionals and the public [38]. The 11 symptoms
were: a persistent pain in the abdomen, a persistent
pain in the pelvis, vaginal bleeding after the meno-
pause, persistent abdominal bloating, increased ab-
dominal size on most days, not wanting to eat
because feel persistently full, difficulty eating usual
amounts of food on most days, passing more urine
than usual, a change in bowel habits, extreme tired-
ness and back pain. Scores were summed to give a
total knowledge score (range 0-11). Confidence in
symptom detection was assessed by asking “How
confident are you that you would notice a symptom
of ovarian cancer?” Scores ranged from 1 (not at all)
to 4 (very confident) [37].
Cues to action
Personal experience with ovarian cancer was assessed
through the question “Have you, or any friends or family
members that are close to you, ever been diagnosed with
Table 1 Demographic characteristics of study participants
Variable Increased risk (n=283) Population risk (n=1043) Statistic Cohen’s d
Age, years M=52.87(sd=10.40) M=64.53 (sd=9.49) t(1313)=-17.86, p < 0.001 1.20
30-49 n (%) 123 (43.9%)
50-69 135 (48.2%) 735 (71%)
70+ 22 (7.9%) 300 (29%)
Relationship status n(%)
Married or cohabiting 209 (74.1%) 515 (49.4%) x2(1)=53.81, p < 0.001 0.41
Education n(%) x2(2)=66.11, p < 0.001
Up to 16 81 (28.7%) 570 (55.8%) 0.46
Secondary 105 (37.2%) 254 (24.9%)
Degree or above 96 (34.1%) 197 (19.3%)
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ovarian cancer?” Participants who responded ‘yes - self ’
were excluded. Response options were coded as 0 = no
ovarian cancer experience, 1 = ovarian cancer experience.
Likelihood of action
Eleven items were used to develop scales for perceived
benefits and percieved barriers [13, 37]. For eight items
participants were asked to “indicate whether any of the
following might put you off going to the doctor if you
thought you had a symptom of ovarian cancer” (e.g. “I
would be too scared”). The response options were: yes
often (code =3), yes sometimes (code = 2) and no (code
=1). For the remaining three items, participants were
asked “please indicate how much you agree or disagree
with each statement” (e.g. “If found early, ovarian cancer
can often be cured”) rated from 1 (strongly disagree) to
4 (strongly agree).
Likelihood of behaviour
Anticipated presentation was measured by asking “If you
had a symptom that you thought might be a sign of
ovarian cancer, how long would it take you to go to the
doctors from the time you first noticed the symp-
tom?”[37]. Response options were: I would go as soon as
I noticed, up to one week, over one week up to two
weeks, over two weeks up to three weeks, over three
weeks up to four weeks, and more than a month.
Responses were re-coded as ‘0 = I would go as soon as I
noticed, no delay’ and ‘1 = any delay, between up to a
week to more than a month’.
Data analysis
Data were examined to determine suitability for ana-
lyses. Screening identified one participant reporting a
score of 15 for ovarian cancer worry (sample mean =
6.15, sd = 1.94) and this outlier case was removed from
analysis. The total increased risk sample (n = 283) and
population risk sample (n = 1043) were combined (n =
1326) for an overall test of the structural relations in the
SEM test of the Health Belief Model (HBM). However,
sample profile characteristics and descriptive statistics
were presented separately for the two groups. In prelim-
inary work to generate measures for the study, separ-
ate principal components analyses of HBM items
were conducted for the two groups in order to iden-
tify the salient factors contributing to the HBM scales
for each risk group.
Increased risk sample Four factors were extracted which
explained a total 63.12% of the variance. The factors were
labelled Perceived Barriers (26.60% of variance, eigenvalue
3.19, Cronbach’s α = 0.72, range 6-8, mean score 7.94, sd
= 2.17), Perceived Benefits (16.42% of variance, eigenvalue
1.97 Cronbach’s α = 0.81, range 3-12, mean score 10.04,
sd = 1.90), Fear (11.57% of variance, eigenvalue 1.39 r
= 0.72, p < 0.001) and Perceived Susceptibility (8.52%,
eigenvalue 1.02). Fear referred to fear of what might be
discovered and therefore for the purpose of SEM, the
factor-derived scales for fear and perceived barriers were
combined to create a perceived barriers construct (8 item
scale Cronbach’s α = .75) in order to create the perceived
barriers item for the likelihood of action component of
the HBM. As the HBM defines the likelihood of action as
perceived benefits minus perceived barriers, these calcula-
tions were made in SPSS (version 18) creating the likeli-
hood of action scale that ranged from −15 to 4. Scores at
the negative end of the Likelihood of Action scale repre-
sented more perceived barriers than benefits, and scores
at the positive end of the scale indicated more perceived
benefits than perceived barriers.
Population risk sample Four factors were extracted
which explained 57.84% of the variance. The factors were
labelled Emotional Barriers (23.96% of variance, eigen-
value 2.88, Cronbach’s α =0.67, range 5-15, mean score
6.02, sd = 1.65), Practical Barriers (15.71% of variance,
eigenvalue 1.89, Cronbach’s α = 0.59, range 3-9 mean score
3.51, sd = 1.02), Perceived Benefits (9.78, eigenvalue 1.17,
Cronbach’s α = 0.68, range 3-12 mean score 10.94, sd =
1.29) and Perceived Susceptibility (8.39% of variance,
eigenvalue 1.01). Similarly to the increased risk group, the
scales for emotional barriers and practical barriers were
combined to create a perceived barriers construct for use
in SEM (8 item scale Cronbach’s α = .72). Factor analysis
of the 12 HBM constructs showed the same pattern of
underlying constructs for the two risk groups, with the
exception of the perceived barriers constructs that were
created based on the principal components analysis for
each group for the purpose of SEM, where minor item
differences were observed. For the increased risk group,
the extracted factors for perceived barriers differentiated
fear of the discovery of ovarian cancer, with the perceived
barriers construct that was created for the purpose of
SEM consisting of a combination of fear and perceived
barriers items as identified in the principal components
analysis. For the population risk group the extracted
factors differentiated practical barriers involving time
constraints, with the perceived barriers construct that was
created for the purpose of SEM consisting of a
combination of emotional and practical barriers.
Prior to SEM analysis, a measurement model was
created in order to observe whether perceived suscepti-
bility and ovarian cancer worry were part of the same
trait complex of perceived threat. The measurement
model consisting of perceived susceptibility, ovarian can-
cer worry and the latent variable perceived threat can be
seen embedded in the structural model in Fig. 2. The
other HBM components were then added in order to
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create the full structural model. The full SEM examined
relations between this latent threat complex and other
constructs. Specifically, a SEM was computed investigat-
ing whether individual perceptions, modifying factors,
perceived threat, cues to action and likelihood of action
predicted the behavioural outcome of anticipated time
to symptomatic presentation. A baseline model was cre-
ated, with the same parameters used for configural
models for analysis of invariance. The increased risk and
population risk data were analysed simultaneously in a
configural model, and constraints were then applied to
the parameters to test invariance in loadings and struc-
ture across groups (see Table 3). The invariance tests ex-
amined equivalence of model parameters (intercept,
regression coefficients, means, covariance and residuals)
between the two risk groups.
Fit of the SEM models was determined from five fit indi-
ces: (1) chi-square (CMIN) not significant at the .05 level of
significance indicates a model with good fit [39]; (2) relative
chi-square (CMIN/df) with a ratio within 3:1 indicates
good fit [30]; (3) a comparative fit index (CFI) and (4)
Tucker-Lewis Index (TLI) greater than .95 indicates a
model with good fit [40], (5) a standardised root-mean
square error of approximation (RMSEA) close to .06 indi-
cates good fit [40].
Results
Psychological characteristics for both risk groups are pro-
vided in Table 2. All comparisons were statistically signifi-
cantly different. Women at increased risk anticipated
longer presentation times (p < .001), had less confidence in
symptom detection (p < .01), higher perceived susceptibility
(p < .001), more personal experience with ovarian cancer (p
< .001), lower symptom knowledge (p < .001) and higher
ovarian cancer worry (p < .001) compared to the population
risk women. The population risk women had significantly
better symptom knowledge than the increased risk sample.
Under half of the increased risk sample (n = 115, 40.8%) an-
ticipated presenting immediately after noticing a possible
ovarian cancer symptom, with 50.8% (n = 507) of the popu-
lation risk women anticipating presenting immediately. The
most frequently recognised symptom was persistent ab-
dominal bloating (n = 247, 88.5%) by increased risk women,
and vaginal bleeding after the menopause (n = 912, 92.3%)
by the population risk women (see Fig. 1 for all symptoms).
Passing more urine than usual was least recognised by both
the increased (n = 76, 27.6%) and population risk women
(n = 334, 37.9%).
Structural equation models
Structural equation model for total sample
The full SEM for the total sample is shown in Fig. 2.
The goodness of fit statistic was significant (×
2=115.68,
df = 11, p < .05), indicating a poor fit. Fit indices were
CFI = .90 and RMSEA = .09, indicating marginal good fit,
with TLI = .66 and relative chi-square ×2/df = 10.52 indi-
cating poor fit (see Additional file 1 for correlation
matrix of model variables). The constructs of the HBM
predicted 6% of variance in anticipated presentation.
Perceived susceptibility (β = 85, p < .001) and ovarian
cancer worry (β = .45, p < .001) were both significant in-
dicators of perceived threat in the measurement model
(see Fig. 2). The correlation between perceived threat
and anticipated presentation was not significant (β =
−.01, p > .05). The likelihood of action construct, which
consists of perceived benefits and barriers, was nega-
tively correlated with anticipated presentation, indicating
that perceiving more benefits than barriers was associ-
ated with reduced presentation times (β = −.25, p < .001).
Knowledge was not correlated with perceived threat (β
= .01, p > .05); but was positively correlated with likeli-
hood of action (β = .15, p < .05) and confidence in symp-
tom detection (β = .24, p < .001). Confidence in symptom
detection was negatively correlated with perceived threat
(β = −.10, p < .01) and positively correlated with likeli-
hood of action (β = .14, p < .001).
A test of invariance was carried out to identify differ-
ences in fit for the measurement model between the in-
creased and population risk groups (see Table 3).
Goodness of fit statistics for the configural model were
×2(118.28), df = 24, p < .001, ×2/df = 4.93, CFI = .77,
RMSEA = .05. The difference in chi-square indicated in-
variance for Model 1, indicating that when the structural
weights (i.e., path coefficients) were constrained across
the two groups there was no significant difference from
the configural model. When other constraints were suc-
cessively added (intercepts, means, covariances, resid-
uals, see Models 2-5 in Table 3) there was a significant
difference between models 2-5 and the configural model.
Due to the invariance, multi-group analysis was con-
ducted to identify model differences between the two
risk groups. The results of the increased risk SEM and
the population risk SEM are presented together in Fig. 3.
Determinants of anticipated presentation in increased risk
sample
The goodness of fit statistic was significant at the .05
level (×
2=23.54, df = 12, p < .05), indicating bad fit. The
relative chi-square (×
2/df = 1.96) was under the recom-
mended 3:1 range and indicated good fit. The CFI = .92
indicated marginal good fit, RMSEA = .06, good fit, and
TLI = .76 a bad fit. The constructs of the HBM predicted
14% of variance in anticipated presentation for the in-
creased risk group (see Fig. 3). The observed relation-
ships between the variables in the increased risk model
are provided in the correlation matrix in Additional file
1. Figure 3 shows that perceived threat was determined
by perceived susceptibility (β = .35, p < .001) and ovarian
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cancer worry (β = .98, p < .001), with both of these variables
significant indicators of perceived threat in this measure-
ment model. Perceived threat was negatively associated
with anticipated presentation in this group (β = −.18, p
< .01). Confidence in symptom detection was negatively as-
sociated with perceived threat (β = −.15, p < .05). Know-
ledge was not correlated with either perceived threat (β
= .10, p > .05) or likelihood of action (β = .11, p > .05). How-
ever, a positive covariance of knowledge with confidence in
symptom detection was observed (β = .31, p < .001). Age
was negatively correlated with perceived threat (β = −.18, p
< .01) and positively correlated with likelihood of action (β
= .23, p < .001). Personal experience was not correlated
with perceived threat (β = .06, p > .05), but those with per-
sonal experience had significantly higher confidence in
symptom detection (β = .18, p < .01). Perceiving more ben-
efits than barriers was associated with earlier anticipated
presentation (β = −.34, p < .001).
Fig. 1 Recognition of individual ovarian cancer symptoms for both risk groups. Legend: valid % presented in cases where data were missing
Table 2 Characteristics of the increased risk and general population samples
Variable Increased risk (n = 283) Population risk (n = 1043) Statistic
Anticipated time to presentation n (%) Any delay (167, 59.2%) Any delay (491, 49.2%) x2(5)=30.38, p < 0.001
I would go as soon as I noticed 115 (40.8%) 507 (50.8%)
Up to 1 week 46 (16.3%) 239 (23.9%)
Over 1 up to 2 weeks 43 (15.2%) 101 (10.2%)
Over 2 up to 3 weeks 23 (8.2%) 51 (5.1%)
Over 3 up to 4 weeks 28 (9.9%) 57 (5.7%)
More than a month 27 (9.6%) 43 (4.3%)
Confidence in symptom detection M(sd) M=2.20 (sd=0.70) M=2.34 (sd=0.93) t(586)=-3.01, p < 0.01
Not at all n (%) 41 (14.5%) 213 (20.9%)
Not very 151 (53.6%) 350 (34.4%)
Fairly 85 (30.1%) 347 (34.1%)
Very 5 (1.8%) 108 (10.6%)
Perceived susceptibility n (%) M=4.21 (sd=0.71) M=2.34 (sd=0.93) t(578)=-34.04, p < 0.001
Much less likely 2 (0.7%) 194 (20.5%)
A little less likely 1 (0.4%) 276 (29.1%)
About the same 30 (11.1%) 392 (41.3%)
A little less likely 144 (53.1%) 69 (7.3%)
Much more likely 94 (34.7%) 17 (1.8%)
Experience with ovarian cancer n (%) x2(1)=437.36, p < 0.001
Yes 257 (90.8%) 238 (22.9%)
Symptom knowledge M (sd, range) 6.1 (2.6, 0-11) 6.9 (2.7, 0-11) t(1324)=–4.28 ,p < 0.001
Worry M (sd, range) 6.2 (1.9, 3-12) 5.3 (1.4, 4-12) t(495)=-6.24, p < 0.001
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Determinants of anticipated presentation in population risk
sample
The goodness of fit statistic was significant at the .05 level
(×
2=26.31, df = 12, p < .05), indicating a bad fit. The relative
chi-square (×
2/df = 2.19) was under the recommended 3:1
range that indicates good fit. Other fit indices were CFI
= .92 and RMSEA = .04, indicating marginally good fit,
with TLI = .72 indicating a bad fit. The constructs of the
HBM predicted 3% of variance in anticipated presentation
for the population risk group (see Fig. 3). The relation-
ships between the variables used in the general population
model are provided in the correlation matrix in Additional
file 1. In the population risk group, perceived susceptibility
was a determinant of perceived threat (β = .64, p < .05),
but worry was not (β = .36, p > .05). The correlation be-
tween perceived threat and anticipated presentation was
not significant in this group (β = −.03, p > .05). Confidence
in symptom detection was associated with perceiving
more benefits than barriers to presentation (β = .17, p
< .001). The correlation between knowledge and likelihood
of action was positive (β = .10, p < .01), with knowledge
associated with perceiving more benefits than barriers
to presenting. Perceiving more benefits than barriers
to presentation was associated with earlier anticipated
presentation (β = −.17, p < .001).
Discussion
In the absence of routine ovarian cancer screening, pro-
moting help-seeking in the presence of symptoms is a
potential route to early diagnosis [28]. The current study
explored determinants of anticipated symptomatic pres-
entation in a sample of women comprising two risk pop-
ulations. Women at increased risk had higher levels of
worry, perceived susceptibility, and a greater degree of
personal experience of ovarian cancer, and lower know-
ledge, and had longer anticipated time to symptom pres-
entation than the general population sample. This is the
first study to compare data on levels of worry and per-
ceived susceptibility in a general population and increased
Fig. 2 SEM for HBM applied to anticipated presentation with potential ovarian cancer symptoms for all participants. Legend: The SEM investigates
whether the HBM variables of individual perceptions (perceived susceptibility and worry), modifying factors (age, knowledge, confidence), perceived threat,
cues to action (personal experience) and likelihood of action (perceived benefits minus barriers) predicted the behavioural outcome of anticipated
presentation for all participants. Values displayed are standardised regression weights (→), covariances (↔) and percentage of variance accounted for.
Squares represent observed variables, and circles represent unobserved variables. ns = not statistically different.*p< .05. **p< .01, ***p< .001. (SEM=
structural equation model, HBM= health belief model)
Table 3 Tests of invariance across different risk groups
x2 Df Δx2 Δdf CFI ΔCFI
Configural model 118.28 24 0.77
Model 1 132.57 32 14.29 8 0.75 0.02
Model 2 201.47 33 83.19* 9 0.58 0.19
Model 3 793.96 37 675.68* 13 0.00 0.77
Model 4 1076.58 47 958.30* 23 0.00 0.77
Model 5 1236.45 49 1118.17* 25 0.00 0.77
Note. Δx2 =difference in x2 between models; Δdf= difference in degrees of
freedom between models; ΔCFI = difference in CFI between models. Numbers
in bold indicate goodness of fit. Model 1= constrained structural weights.
Model 2= constrained structural weights and intercepts. Model 3 =
constrained structural weights, intercepts and means. Model 4= constrained
structural weights, intercepts, means and covariance’s. Model 5 = constrained
structural weights, intercepts, means, covariance’s and residuals. *p<.05
Smits et al. BMC Cancer  (2017) 17:814 Page 7 of 11
risk sample, and to examine how worry and perceived sus-
ceptibility interact with help-seeking intentions. Findings
suggest that health beliefs relating to ovarian cancer are
related to risk status. Determinants of earlier symptomatic
presentation that were common to both groups included
high perceived susceptibility, high confidence in symptom
detection, high symptom knowledge and perceiving more
benefits than barriers to presentation. However, the cancer
worry component of perceived threat was a unique pre-
dictor in the increased risk group. The current findings
support the need for an ovarian cancer awareness inter-
vention that emphasises the perceived benefits of symp-
tom presentation and minimises perceived barriers, and
that increases confidence in symptom detection whilst
managing worry.
Evidence suggests that higher perceived threat in-
creases the likelihood of engaging in behaviour that is
likely to manage or reduce this threat [17]. The present
findings add to this by suggesting that, in certain patient
groups, worry may be a greater motivator of earlier pres-
entation than the susceptibility component of perceived
threat. Perceived threat was observed to comprise both
worry and susceptibility components in women at in-
creased risk, but only susceptibility aspects in the popu-
lation risk sample. The appraisal process through which
people generate a sense of personal susceptibility could
therefore be an important target for future research on
cancer awareness, helping researchers to better concep-
tualise “delay” from the patient’s perspective [41]. It may
be that emotional processes are more influential in
certain patient groups (such as those at increased
risk) and therefore may need consideration when
conceptualising the symptom appraisal interval. The
current findings could suggest that women at in-
creased risk have perceived susceptibility and ovarian
cancer worry determinants in this appraisal process.
It should be noted that perceived susceptibility partly
reflected a true element (as the increased risk women
genuinely were at risk), highlighting that perceived
susceptibility encompasses many elements (i.e know-
ledge, construal of risk and emotions) that need to be
better understood.
The association between earlier anticipated symptom
presentation and worry in increased risk women in the
current study complements research on familial ovarian
cancer screening uptake, where worry has been shown
to be a key determinant of screening uptake [18, 23].
The findings relating to worry could also have practical
implications for healthcare professionals who should be
aware of the potential for heightened cancer worry when
Fig. 3 SEM for HBM applied to anticipated presentation with potential ovarian cancer symptoms for both groups. Legend: The SEM investigates whether
the HBM variables of individual perceptions (perceived susceptibility and worry), modifying factors (age, knowledge, confidence), perceived threat, cues to
action (personal experience) and likelihood of action (perceived benefits minus barriers) predicted the behavioural outcome of anticipated presentation for
both groups. Increased risk group is the top coefficient (bold and italics), and the general population group is the bottom coefficient (not bold/not italics).
Values displayed are standardised regression weights (→), covariances (↔) and percentage of variance accounted for. Squares represent observed
variables, and circles represent unobserved variables. ns = not statistically significant.*p< .05. **p< .01, ***p< .001. (SEM= structural equation model, HBM=
health belief model)
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consulting with people at increased risk. Results in the
current study indicated that women from the general
population had higher symptom knowledge and antici-
pated presenting in shorter time frames than the in-
creased risk sample. The observed difference could
reflect that women at increased risk in the UK have pre-
viously relied on screening as their main detection strat-
egy and therefore place less emphasis on symptom
knowledge and symptomatic presentation. The type of
knowledge women have about ovarian cancer will also
vary across the lifespan according to maturational and
experiential factors (e.g., reproductive change).
Factor analysis of the HBM scales showed the same
pattern of underlying constructs for the two risk groups,
with the exception of barriers. For the increased risk
sample, barriers were differentiated by fear of the discov-
ery of ovarian cancer, whereas for the population risk
group the practical barriers reflecting time constraints
were more salient. This differentiation is an important
finding and could have implications for education and
awareness about ovarian cancer. The results could sug-
gest that regardless of risk status, all women could bene-
fit from ovarian cancer symptom information and
education about presentation times. Therefore an inter-
vention with tailored content that addresses the specific
needs of women at increased risk could be embedded
within an inclusive tool containing core symptom infor-
mation that addresses generic educational needs.
A greater proportion of variance in anticipated presen-
tation was predicted for the increased risk group (14%)
than for the population risk group (3%). Tests of invari-
ance indicated that the difference between the two groups
was due to differences in the magnitude of path coeffi-
cients in the model, rather than differences in levels of
predictors (e.g. mean susceptibility). The path differences
suggest that health beliefs in women at increased risk are
determined by perceived threat, with emotional represen-
tations of this latent variable important in this population.
The varying model fit could be explained in terms of the
study populations. The model may not fit the general
population so well because it does not represent the health
beliefs of this group, or their notion of threat, as well as it
does for the increased risk group. The HBM proposes that
when faced with a potential health threat, people consider
their susceptibility to and the severity of the health threat
when deciding whether to act, [17], with such consider-
ations more salient in those at increased risk. This could
also explain the greater proportion of variance in antici-
pated presentation that was accounted for by the model in
women at increased risk.
The cross-sectional study design and use of intent-to-
present have implications regarding the temporal stability
and interpretation of the current findings. Although caus-
ality cannot be inferred, the current research provides an
important contribution as it has identified health beliefs in
different risk populations in relation to anticipated symp-
tomatic presentation. It should also be noted that the
current findings may reflect more about cognitive ap-
praisal of what to do in the presence of symptoms (inten-
tions) as opposed to actual behaviour [42], with actual
behaviour possibly less prompt than intentions [12]. In
addition to the use of intentions, the use of a dichotomous
variable for anticipated presentation could obscure nu-
ances in this variable. However, the cut-off of ‘immediate
presentation’ versus ‘any delay’ was chosen in the absence
of clinical consensus regarding the optimal time to present
with ovarian cancer symptoms, and recognising that the
presence of delay may be more important than the degree
of delay [43, 44].
Symptom knowledge scores were aggregated in this
study, whereas a deeper understanding may be gained if
knowledge of individual symptoms, such as specific ver-
sus non-specific symptoms, was examined. However, the
current sample size was insufficient to permit such fine-
grained analysis. In addition, the symptom question does
not inform about the processes women may go through
when appraising and interpreting a symptom, or if in-
deed the participants are simply guessing whether symp-
toms were indicative of ovarian cancer.
Model fit has previously been discussed, but group dif-
ferences should also be noted as a possible explanation
of differences observed in the SEM. The demographic
profiles of the two samples, for example variables includ-
ing age and education level rather than cancer awareness
could explain the observed effects. The potential lack of
sample representativeness is also acknowledged, as the
increased risk women were recruited from those who
had participated in a screening evaluation study. These
women may therefore have different levels of ovarian
cancer worry and symptom knowledge than women who
did not take part. The limitations of sampling methods
are also acknowledged, since the cases and controls were
not drawn from the same population [45]. A further
concern is the different sampling methods that were
used. The increased genetic risk sample was an oppor-
tunity sample whilst the general population sample was
a population representative sample. The demographic
profiles of the two samples could explain differences ob-
served, therefore it could be variables including age and
education level, rather than cancer awareness that
caused the observed effects.
Conclusions
The current research has developed an understanding of
anticipated presentation with ovarian cancer symptoms.
In both risk populations, raising awareness of the bene-
fits of presenting with symptoms and dispelling the bar-
riers is important. Prospective research that examines
Smits et al. BMC Cancer  (2017) 17:814 Page 9 of 11
actual behaviour and that disentangles causal direction is
an important next step in this research field. This study
highlights the need to develop an ovarian symptom in-
formation tool in which content is tailored according to
ovarian cancer risk.
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